glp-1 super responders Super-Responders” to Liraglutide Monotherapy and the Growing Evidence of Efficacy of Analogues in Obesity Management: A Longitudinal Prospective Cohort Study non responder to glp 1

Some patients have shared what they describe as unexpected behavioral shifts, such as naturally drinking less alcohol or feeling less drawn to certain habits

That might include setting stricter eligibility criteria for GLP-1 coverage, limiting the duration of coverage for weight loss, or aligning pricing with outcomes through partnerships with point-solution vendors

& Lyumkis, D

Both are GLP-1 receptor agonists, but they work through slightly different mechanisms

In combination with intensive behavioral therapy for weight loss, individuals (total n=611) in another study (note: funded by Novo-Nordisk) on semaglutide lost 16% of their body weight compared to 5.7% in the placebo control group